Pfiz­er, still chas­ing Dupix­ent, re­leas­es fifth round of da­ta for eczema JAK in­hibitor abroc­i­tinib

Over the last sev­er­al months, Pfiz­er has been putting to­geth­er a pro­file of sev­er­al Phase III tri­als for its ex­per­i­men­tal JAK1 in­hibitor abroc­i­tinib to take to reg­u­la­tors, in the hopes of tak­ing down Dupix­ent. And on Wednes­day, the big phar­ma re­leased an­oth­er set of pos­i­tive topline da­ta.

In what’s now the fifth Phase III to re­port abroc­i­tinib da­ta, Pfiz­er said few­er pa­tients with atopic der­mati­tis ex­pe­ri­enced a flare up af­ter 52 weeks at mul­ti­ple dosage lev­els over place­bo. The study, which en­rolled 1,233 pa­tients 12 and old­er, in­volved a 12-week in­duc­tion fol­lowed by a 40-week blind­ed main­te­nance pe­ri­od.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.